## Kelly L Singel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6249331/publications.pdf

Version: 2024-02-01

19 papers	982 citations	13 h-index	940533 16 g-index
20	20	20	2184
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 2355-2369.	4.2	5
2	RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. Communications Biology, 2021, 4, 102.	4.4	28
3	Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. Cancer Immunology Research, 2021, 9, 790-810.	3.4	29
4	Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunology Research, 2020, 8, 819-828.	3.4	25
5	Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. British Journal of Cancer, 2019, 120, 207-217.	6.4	62
6	Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight, 2019, 4, .	5.0	93
7	Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. Journal of Allergy and Clinical Immunology, 2018, 141, 1028-1035.	2.9	172
8	Mature neutrophils suppress T cell immunity in the ovarian cancer microenvironment via C3 activation. Molecular Immunology, 2018, 102, 215.	2.2	1
9	Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecologic Oncology, 2017, 146, 491-497.	1.4	53
10	Abstract 4557: Tumor immune profiling identifies multiple unique therapeutic targets that improve vaccination $\pm$ oncolytic virotherapy against metastatic ovarian cancer., 2017,,.		0
11	Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunological Reviews, 2016, 273, 329-343.	6.0	140
12	NOX2-dependent regulation of inflammation. Clinical Science, 2016, 130, 479-490.	4.3	155
13	Cancer in primary immunodeficiency diseases: An analysis of cancer incidence in the United States immune deficiency network (USIDNET) registry Journal of Clinical Oncology, 2016, 34, 1520-1520.	1.6	1
14	Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor- $\hat{l}\pm$ and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 352-357.	1.4	70
15	Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget, 2015, 6, 11310-11326.	1.8	45
16	Effect of cell-free ascites containing mitochondrial DNA (mtDNA) from ovarian cancer (OC) patients on human neutrophils and neutrophil extracellular traps (NETs) Journal of Clinical Oncology, 2014, 32, e22087-e22087.	1.6	0
17	Pretreatment serum mitochondrial DNA (mtDNA) correlates with shorter progression-free and overall survival in patients with advanced ovarian cancer (OC) Journal of Clinical Oncology, 2014, 32, 5545-5545.	1.6	0
18	Monocyte- and Macrophage-Targeted NADPH Oxidase Mediates Antifungal Host Defense and Regulation of Acute Inflammation in Mice. Journal of Immunology, 2013, 190, 4175-4184.	0.8	75

#	Article	IF	CITATIONS
19	Myeloid-Derived Suppressor Cells Modulate Immune Responses Independently of NADPH Oxidase in the Ovarian Tumor Microenvironment in Mice. PLoS ONE, 2013, 8, e69631.	2.5	28